Behavioral Health Business August 26, 2024
Ketamine therapy provider HOPE Therapeutics announced it plans to acquire five ketamine clinics and reach $100 million in annual revenue in less than a year.
HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals (Nasdaq: NRXP), announced on Monday that it has secured $30 million in debt to finance the acquisitions. The company is apparently targeting five unspecified clinics in the Western U.S.
“We are delighted to take the critical first steps towards developing a network of clinics that can provide the highest possible level of care and demonstrate best practices for mental health professionals around the world,” the company’s leadership said in a statement.
Jonathan Javitt and Matthew Duffy are co-CEOs of HOPE Therapeutics.
HOPE Therapeutics also plans to expand...